Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome

作者：Danlos Francois Xavier; Rossi Giovanni Maria; Blockmans Daniel; Emmi Giacomo; Kronbichler Andreas; Durupt Stephan; Maynard Claire; Luca Luminita; Garrouste Cyril; Lioger Bertrand; Mourot Cottet Rachel; Dhote Robin; Arlet Jean Benoit; Hanslik Thomas; Rouvier Philippe; Ebbo Mikael; Puechal Xavier; Nochy Dominique; Carlotti Agnes; Mouthon Luc; Guillevin Loic; Vaglio Augusto; Terrier Benjamin^*

来源：Autoimmunity Reviews, 2017, 16(10): 1036-1043.

DOI：10.1016/j.autrev.2017.07.020

• ANCA-associated vasculitis
• Granulomatosis with polyangiitis (GPA)
• IgG4-related disease

Objective: Atypical manifestations have been described in patients with ANCA-associated vasculitides (AAV), such as pachymeningitis, orbital mass or chronic periaortitis. Because these manifestations have been associated to the spectrum of IgG4-related disease (IgG4-RD), we hypothesized that both diseases could overlap. Methods: We conducted a European retrospective multicenter observational study including patients fulfilling ACR and Chapel Hill criteria for MV and IgG4-RD Comprehensive Diagnostic Criteria. Results: Eighteen patients were included (median age 55.5 years, 13 men). AAV and IgG4-RD were diagnosed concomitantly in 13/18 (72%) patients; AAV preceded IgG4-RD in 3/18 (17%) while IgG4-RD preceded MV in 2/18 (11%). MV diagnoses included granulomatosis with polyangiitis in 14 (78%), microscopic polyangiitis in 3 (17%), and eosinophilic granulomatosis with polyangiitis in one case. IgG4-RD diagnosis included definite IgG4-RD in 5 (28%) cases, probable IgG4-RD in 5 (28%) and possible IgG4-RD in 8 (44%). IgG4-RD manifestations were chronic periaortitis in 9/18 (50%) patients, orbital mass and tubulointerstitial nephritis in 4 (22%) cases, prevertebral fibrosis in 3 (17%), pachymeningitis and autoimmune pancreatitis in 2 (11%) cases. Patients required median number of 2 (range 0-4) lines of immunosuppressants in combination with glucocorticoids. During the follow-up (median 49,8 months, range 17,25-108 months), MV manifestations relapsed in 10/18 (56%) cases and IgG4-RD lesions in 5/18 (28%). When used, mainly for relapses, rituximab showed response in all cases. Conclusion: MV and IgG4-RD may overlap. Clinicians should consider that atypical manifestations during MV could be related to IgG4-RD rather than to refractory granulomatous or vasculitic lesions.

• 出版日期2017-10